Table 2. Clinical features, HBV genotype, and additional N-glycosylation mutation in the 288 patients with coexistence of HBsAg/anti-HBs enrolled in the study.
| Item | HCC ( n = 76) | Non-HCC ( n = 212) | P value |
|---|---|---|---|
| Age | 53.03 ± 10.50 | 43.99 ± 9.89 | < 0.001 |
| Male [n (%)] | 60 (78.94%) | 174 (82.08%) | 0.549 |
| HBV DNA (log10 IU/L) | 4.82 ± 1.61 | 5.32 ± 1.69 | 0.041 |
| Anti-HBs (IU/L) | 52.04 (26-140) | 42.97 (22-100) | 0.085 |
| TBIL (μmol/L) | 19.25 (12-27) | 16.75 (10-32) | 0.146 |
| ALT (U/L) | 31 (26-39) | 49.5 (22-44) | < 0.001 |
| ALB (g/L) | 32.11 ± 6.25 | 37.22 ± 8.12 | < 0.001 |
| AFP (ng/mL) | 28.15 (11-452) | 11 (6-31) | < 0.001 |
| CHE (U/L) | 6406 ± 1663.68 | 5368 ± 2299.46 | 0.001 |
| HBV genotype C | 75 (98.68%) | 198 (93.40%) | 0.075 |
| N-glycosylation mutations [n (%)] | 17 (22.38%) | 17 (8.0%) | 0.001 |
TBIL, total bilirubin; ALT, alanine aminotransferase; ALB, albumin; AFP, alpha-fetoprotein; CHE, cholinesterase. Chi-squared, Student t test analysis, and nonparametric Wilcoxon signed-ranked test were used. A P value less than 0.05 was considered to be statistically significant.